SAN FRANCISCO--(BUSINESS WIRE)--
Fantex, Inc. confirmed reports today that Arian Foster will undergo season ending back surgery, and as a result Fantex, Inc. announced that it is postponing the offering for Fantex Series Arian Foster Convertible Tracking Stock (“Fantex Arian Foster”).
“After consideration, we have made the decision to postpone the offering for Fantex Arian Foster,” said Buck French, CEO, Fantex, Inc. “We feel this is a prudent course of action under the current circumstances. We continue to support Arian and his brand, and we wish him well in his recovery. We will continue to work with him through his recovery and intend to continue with this offering at an appropriate time in the future based on an assessment of these events.”
Fantex, Inc. has filed a registration statement (including a prospectus) with the SEC for the offering to which this communication relates. This investment is complex, risky and speculative. Before you invest, you should read the prospectus in that registration statement and other documents Fantex, Inc. has filed with the SEC for more complete information about Fantex, Inc. and this offering. You may get these documents for free by visiting EDGAR on the SEC Website at www.sec.gov. Alternatively, Fantex, Inc., any underwriter or any dealer participating in the offering will arrange to send you the prospectus if you request it by calling toll-free 866-315-3482. View the prospectus: https://fantex.com/fantex-arian-foster-266729/prospectus
About Fantex Inc.
Based in San Francisco, Fantex, Inc. is a brand building company that purchases a minority interest in an athlete brand and works to increase the value of the brand. In order to fund the purchase, Fantex, Inc. develops a tracking stock that is linked to the economic performance of the brand.